Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof

US10040852B2 · kind B2 · utility

Assignees

• Abb Vie Deutschland Gmbh & Co. KG · DE
• Abb Vie Inc. · US

Inventors

• Mario Mezler · Ludwigshafen, DE
• Achim Moeller · Grünstadt, DE
• Reinhold Mueller · Schifferstadt, DE
• Bernhard Mueller · Neustadt, DE
• Tariq Ghayur · Holliston, US
• Eve H. Barlow · Princeton, US
• Martin Schmidt · Frankfurt am Main, DE
• Axel Meyer · Frankfurt am Main, DE
• Nicole Teusch · Uerdingen, DE

Key dates

• Filing date: Jan 6, 2016
• Grant date: Aug 7, 2018
• Expiry date: Jan 6, 2036

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.